Alector, Inc. (NASDAQ:ALEC) Given Consensus Rating of “Hold” by Brokerages

Alector, Inc. (NASDAQ:ALEC – Get Rating) has earned an average recommendation of “Hold” from the nine research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $15.13.

A number of analysts recently issued reports on the stock. Citigroup lowered their price target on shares of Alector from $17.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, March 1st. Morgan Stanley lowered their price target on Alector from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Friday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $41.00 price target on shares of Alector in a research report on Wednesday, March 1st. Mizuho decreased their price objective on shares of Alector from $15.00 to $12.00 in a report on Friday, March 3rd. Finally, Barclays decreased their price objective on shares of Alector from $14.00 to $12.00 in a report on Friday, May 5th.

Insider Transactions at Alector

In other news, CEO Arnon Rosenthal sold 15,186 shares of the firm’s stock in a transaction dated Friday, March 17th. The shares were sold at an average price of $6.22, for a total value of $94,456.92. Following the transaction, the chief executive officer now directly owns 1,656,350 shares of the company’s stock, valued at $10,302,497. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Gary Romano sold 3,238 shares of Alector stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $8.32, for a total transaction of $26,940.16. Following the transaction, the insider now owns 104,737 shares in the company, valued at $871,411.84. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Arnon Rosenthal sold 15,186 shares of Alector stock in a transaction that occurred on Friday, March 17th. The stock was sold at an average price of $6.22, for a total value of $94,456.92. Following the transaction, the chief executive officer now owns 1,656,350 shares in the company, valued at approximately $10,302,497. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,564 shares of company stock valued at $180,802. Corporate insiders own 12.89% of the company’s stock.

Hedge Funds Weigh In On Alector

A number of institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in Alector by 2.9% during the first quarter. BlackRock Inc. now owns 7,583,916 shares of the company’s stock worth $46,944,000 after purchasing an additional 215,296 shares during the period. FMR LLC grew its holdings in shares of Alector by 35.6% during the 1st quarter. FMR LLC now owns 6,387,376 shares of the company’s stock worth $39,538,000 after purchasing an additional 1,675,436 shares during the period. Federated Hermes Inc. grew its holdings in shares of Alector by 12.3% during the 1st quarter. Federated Hermes Inc. now owns 5,931,034 shares of the company’s stock worth $84,517,000 after purchasing an additional 650,187 shares during the period. Vanguard Group Inc. grew its holdings in shares of Alector by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 5,753,194 shares of the company’s stock worth $54,426,000 after purchasing an additional 44,498 shares during the period. Finally, State Street Corp grew its holdings in shares of Alector by 2.0% during the 2nd quarter. State Street Corp now owns 3,914,336 shares of the company’s stock worth $39,770,000 after purchasing an additional 78,243 shares during the period. 64.96% of the stock is owned by hedge funds and other institutional investors.

Alector Stock Up 1.0 %

Shares of ALEC opened at $7.75 on Wednesday. Alector has a 52 week low of $5.76 and a 52 week high of $13.50. The company has a market capitalization of $645.96 million, a price-to-earnings ratio of -4.78 and a beta of 0.79. The stock’s 50-day moving average price is $6.69 and its 200-day moving average price is $7.94.

Alector (NASDAQ:ALEC – Get Rating) last issued its earnings results on Tuesday, February 28th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.09). Alector had a negative return on equity of 57.31% and a negative net margin of 107.05%. The company had revenue of $14.44 million during the quarter, compared to analysts’ expectations of $35.37 million. As a group, equities analysts anticipate that Alector will post -3.06 EPS for the current fiscal year.

Alector Company Profile

(Get Rating)

Alector, Inc operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies.